Palisade Bio Announces Exercise of Previously Issued Warrants for $2.5 Million

January 30, 2024

https://www.globenewswire.com/news-release/2024/01/30/2820114/0/en/Palisade-Bio-Announces-Exercise-of-Previously-Issued-Warrants-for-2-5-Million.html

Carlsbad, CA, Jan. 30, 2024 (GLOBE NEWSWIRE) — Palisade Bio, Inc.  (Nasdaq:PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced an agreement between the Company and several accredited investors to exercise certain existing warrants (the “Existing Warrants”) to purchase up to an aggregate of 3,413,286 shares of common stock. The Existing Warrants had initial exercise prices of $35.525, $2.375, and 2.64, respectively, and were issued by the Company on May 10, 2022, January 4, 2023, and April 5, 2023, respectively, with each exercise occurring at a reduced exercise price of $0.7313 per share.

Read more at globenewswire.com

Related news for (PALI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.